Keywords
Heart Failure
Sodium-Glucose Transporter 2 Inhibitors
How to Cite
Copyright © | All rights reserved.
The journal holds the exclusive copyright for the publication of this article under the terms of Brazilian law 9610/98.
Partial reproduction
The use of parts of the texts, figures and questionnaire of the article is free, being mandatory the citation of the authors and journal.
Total reproduction
It is expressly prohibited and must be authorized by the journal.
Abstract
Objective: To analyze the benefits of prescribing sodium-glucose cotransporter 2 inhibitors in patients with heart failure. Thus, evaluating the reduction of cardiovascular events in these patients. Methods: The methodological approach of this work advocates a compilation of bibliographic research with a qualitative approach and descriptive character through an extensive literature review. The databases used were PubMed and BVS. The search for articles was performed using the descriptors: “heart failure”, “sodium-glucose transporter 2 inhibitors”, “mortality” and “aged”. Inclusion criteria were randomized or non-randomize controlled clinical trial articles, incidence study, prevalence study, open access articles, articles published in English, Portuguese, Spanish, elderly people aged 65 years or older, in the range from 2020 to 2022. Results: The advantages of using SGLT2 inhibitors in the treatment of heart failure were evaluated, showing positive results in reducing mortality, hospitalizations and improving quality of life. Final Considerations: Thus, it was observed that, with the use of these drugs, the morbidity and mortality rates of patients with HF reduced considerably, leading to a decrease in the number of hospitalized patients.
References
ARAÚJO AA, et al. Perfil epidemiológico e clínico de pacientes acometidos por insuficiência cardíaca. Revista de enfermagem UFPE, 2014; 8(3): 509-513.
ARIAS A. Dapagliflozina mejoraría desenlaces clínicos en pacientes con insuficiencia cardiaca y fracción de eyección reducida. Evid actual práct ambul, 2020; e002044–e002044.
BASSI NS, et al. Association of Optimal Implementation of Sodium-Glucose Cotransporter 2 Inhibitor Therapy With Outcome for Patients With Heart Failure. JAMA Cardiology, 2020; 5(8): 948–951.
BENNETT JA, et al. Validity and reliability of the NYHA classes for measuring research outcomes in patients with cardiac disease. Heart & Lung, 2002; 31(4): 262–270.
BERG DD, et al. Time to Clinical Benefit of Dapagliflozin and Significance of Prior Heart Failure Hospitalization in Patients With Heart Failure With Reduced Ejection Fraction. JAMA Cardiol, 2021; 6(5): 499–507.
BROWN E, et al. SGLT2 inhibitors and GLP-1 receptor agonists: established and emerging indications. The Lancet, 2021; 398: 262–276.
BUTT JH, et al. Efficacy and Safety of Dapagliflozin in Men and Women With Heart Failure With Reduced Ejection Fraction: A Prespecified Analysis of the Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure Trial. JAMA Cardiol, 2021; 6(6): 678–689.
CASTRO RA, et al. Adesão ao tratamento de pacientes com insuficiência cardíaca em um hospital universitário. Rev Gaúcha Enferm, 2010; 31: 225–231.
CORREIA ETO, et al. Chegou a Hora de uma Nova Terapia Padrão para a Insuficiência Cardíaca com Fração de Ejeção Reduzida? Arq Bras Cardiol, 2021; 117: 149–152.
COWIE MR. Sodium-glucose cotransporter-2 inhibitors: where and when? Future Cardiol, 2021; 17(3): 403–406.
CREBER RM, et al. Psychometric properties of the Kansas City Cardiomyopathy Questionnaire (KCCQ). European Journal of Cardiovascular Nursing, 2012; 11(2): 197–206.
DOCHERTY KF, et al. Effect of Dapagliflozin on Outpatient Worsening of Patients With Heart Failure and Reduced Ejection Fraction: A Prespecified Analysis of DAPA-HF. Circulation, 2020; 142(17): 1623–1632.
DOCHERTY KF, et al. Extrapolating Long-term Event-Free and Overall Survival With Dapagliflozin in Patients With Heart Failure and Reduced Ejection Fraction: An Exploratory Analysis of a Phase 3 Randomized Clinical Trial. JAMA Cardiol, 2021; 6(11): 1298–1305.
FILION KB, et al. Sodium glucose cotransporter 2 inhibitors and risk of major adverse cardiovascular events: multi-database retrospective cohort study. BMJ, 2020; m3342–m3342.
GROENEWEGEN A, et al. Epidemiology of heart failure. European J of Heart Fail, 2020; 22(8): 1342–1356.
INZUCCHI SE, et al. Cardiovascular Benefit of Empagliflozin Across the Spectrum of Cardiovascular Risk Factor Control in the EMPA-REG OUTCOME Trial. J Clin Endocrinol Metab, 2020; 105(9): dgaa321.
JANUZZI JL, et al. Effects of Canagliflozin on Amino-Terminal Pro-B-Type Natriuretic Peptide: Implications for Cardiovascular Risk Reduction. J Am Coll Cardiol, 2020; 76(18): 2076–2085.
KEMP C e CONTE JV. The pathophysiology of heart failure. Cardiovasc Pathol, 2012; 21(5): 365–371.
KHUNTI K, et al. Cardiovascular outcomes with sodium-glucose cotransporter-2 inhibitors vs other glucose-lowering drugs in 13 countries across three continents: analysis of CVD-REAL data. Cardiovasc Diabetol, 2021; 159–159.
KOSIBOROD MN, et al. Effects of Dapagliflozin on Symptoms, Function, and Quality of Life in Patients With Heart Failure and Reduced Ejection Fraction: Results From the DAPA-HF Trial. Circulation, 2020; 141(2): 90–99.
LEÓN P DE e JIMENA N. La empagliflozina disminuye la mortalidad cardiovascular y el riesgo de hospitalización en pacientes con insuficiencia cardíaca. Evid actual práct ambul, 2021; e002159–e002159.
LIN DS-H, et al. The efficacy and safety of novel classes of glucose-lowering drugs for cardiovascular outcomes: a network meta-analysis of randomised clinical trials. Diabetologia, 2021; 2676–2686.
MILDER DA, et al. Sodium-glucose co-transporter type-2 inhibitors: pharmacology and peri-operative considerations. Anaesthesia, 2018; 73(8): 1008–1018.
OLIVEIRA JMG. Papel prognóstico do estado volêmico na insuficiência cardíaca agudamente descompensada: análise mediada por NT-ProBNP. Dissertação (Mestrado em Medicina e Saúde Humana) - Escola Bahiana de Medicina e Saúde Pública, Salvador, 2016; 44 p.
PACKER M, et al. Effects of Sodium-Glucose Cotransporter 2 Inhibitors for the Treatment of Patients With Heart Failure: Proposal of a Novel Mechanism of Action. JAMA Cardiology, 2017; 2(9): 1025–1029.
PACKER M, et al. Empagliflozin in Patients With Heart Failure, Reduced Ejection Fraction, and Volume Overload: EMPEROR-Reduced Trial. J Am Coll Cardiol, 2021; 1381–1392.
SANTOS FD. Insuficiência Cardíaca no Idoso: etiologia, diagnóstico, tratamento e prognóstico. Dissertação (Mestrado em Medicina - Área: Cardiologia) – Universidade do Porto, Portugal, 2011; 26 p.
YEOH SE, et al. Patient Characteristics, Clinical Outcomes, and Effect of Dapagliflozin in Relation to Duration of Heart Failure: Is It Ever Too Late to Start a New Therapy? Circ Heart Fail, 2020; 13(12): e007879.
ZELNIKER TA e BRAUNWALD E. Mechanisms of Cardiorenal Effects of Sodium-Glucose Cotransporter 2 Inhibitors. Journal of the American College of Cardiology, 2020; 75(4): 422–434.